Linda Duska retweeted
During the #SGOMtg, Linda Duska, MD (@LDuska) from @uvamedicine shares encouraging insights into the overall survival and progression-free survival results from the ENGOT-cx11/GOG-3047/KEYNOTE-A18 study based on the second interim analysis.
#MoffittSGO25 #SGO2025 #SGOAM2025 #MultipleYourImpact #CancerResearch #CervicalCancer
Linda Duska retweeted
Our first interview of the day was with @LDuska of @uvamedicine, who shared key OS and PFS2 data from the second interim analysis of the KEYNOTE-A18 study. Hear a brief preview of her research below, and check out onclive.com for more details! @SGO_org #SGOMtg #gynsm
Linda Duska retweeted
The SGO released a clinical practice advisory addressing the nationwide shortage of intravenous (IV) solutions. These guidelines outline strategy considerations to manage the shortage in various settings while maintaining high-quality patient care.
shorturl.at/q75yR
Linda Duska retweeted
#IGCS 2024 Thoughtful, excellent distillation by Dr Ramez Eskander on role of IO in endometrial cancer including the unknown, encourages care in interpreting data @SGO_org @UMassChan
Linda Duska retweeted
Congratulations Shannon on updated results on DUO-E at #igcs2024
Linda Duska retweeted
🎉A clear win at #IGCS2024!! Cadonilimab added to chemotherapy yielded improved improved progression free and overall in recurrent #cervicalcancer #gyncsm
Linda Duska retweeted
Exciting poster presentations - video with Dr Brown capturing her thoughts on the BOUQUET trial 💐❤️💐
Linda Duska retweeted
Congratulations Dr Westin and all DUO-E investigator!! Provocative data regarding combination durva + olaparib in patients with endometrial cancer - role of biomarkers??to direct combination vs IO only maintenance therapy. Impressive PFS!
























































